Androgen Receptor Pathway Inhibitors (ARPIs)

DRUG2 trials

Sponsors

Ankara Etlik City Hospital, Affidea Nu-med Center of Oncological DIagnostics and Therapy

Conditions

BrachytherapyDose Escalation: Solid TumorsMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Prostate CancerRegionally Advanced Prostate CancerStereotactic Body Radiation Therapy (SBRT)

Phase 2

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

RecruitingNCT07426094

Affidea Nu-med Center of Oncological DIagnostics and TherapyBrachytherapy, Dose Escalation: Solid Tumors, Prostate Cancer +2

Start: 2026-03-19End: 2035-12-01Target: 600Updated: 2026-07-21

Unknown Phase

Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

RecruitingNCT07181122

Ankara Etlik City HospitalMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Start: 2025-10-22End: 2026-09-15Target: 102Updated: 2026-04-28